Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FLUCOP

Financiado

Cerrado

Standardization and Development of Assays for Assessment of Influenza Vaccines C...

Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at m... ver más

29/02/2020

SANOFI PASTEUR SA

14M€

Presupuesto del proyecto: 14M€

Líder del proyecto

SANOFI PASTEUR SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 24 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2020-02-29 No tenemos la información de la convocatoria

0% 44% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

24 Participantes

SANOFI PASTEUR SA

0.00€ | Lider

HVL

N.D. | Participante

UNIPG

N.D. | Participante

QUINTEN SAS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FLUCOP Standardization and Development of Assays for Assessment of... 14M€ Cerrado

FluPRINT Tracing the inFLUenza vaccine imPRINT on immune system to id... 270K€ Cerrado

IRINVAC IMMUNE RESPONSES TO INFLUENZA VACCINE 100K€ Cerrado

IMECS Identification of Mechanisms Correlating with Susceptibility... 4M€ Cerrado

PID2019-105761RB-I00 ESTUDIO DE PATOGENICIDAD ASOCIADA A LA INFECCION POR VIRUS D... 106K€ Cerrado

FLUNIVAC InFLUenza virus UNIVersal VACcine development program 7M€ Cerrado

Líder del proyecto

SANOFI PASTEUR SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 14M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease. Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the currently criteria of correlates of protection(CoP) show limitations in predicting protection for seasonal and pandemic vaccines. The Haemagglutinin Inhibition(HAI) antibody titre is the most widely used CoP for seasonal influenza vaccine even if there is a lack of standardisation for conducting HAI and other serological assays and therefore results obtained from different laboratories are not comparable. This leads to the urgent need of improving international standardisation of serological assays to reduce inter laboratory variability and to generate supportive immunological assays to be used in studies aimed at developing clinically relevant surrogate markers of protection of influenza vaccines. Objectives: The main long-term aim of the FLUCOP project is to improve and standardize the existing immunological assays and to develop new assays for the better evaluation of the CoP of influenza vaccines. Main specific FLUCOP objectives include: - achieve standardization of HAI and Virus Neutralization(VN) assays; - promote the understanding and application of Cell-Mediated Immunity (CMI) and Neuraminidase (NA) assays as tools for the evaluation of influenza vaccines; - develop selective new assays which might potentially used for future clinical trials for influenza seasonal vaccine evaluation FLUCOP Consortium and Project Impact: The FLUCOP consortium brings together 26 groups from 7 European countries, and includes contributors from the academic, governmental, non-for-profit and pharmaceutical sectors. As a whole, the consortium has a balanced array of expertise and each group has been carefully selected to avoid overlaps in research activities and to collectively address the planned objectives. FLUCOP is expected to have a significant impact to improve and standardize the existing immunological assays and develop new assays to better evaluate influenza vaccines. This will contribute to the future clinical trial evaluation and possible establishment of correlates of protection Through a public-private collaboration FLUCOP will reach a common agreement on assays and methods to be used by all groups both from the public and private sector for testing influenza vaccines in humans. These efforts are expected to aid evolution of the regulatory guidelines and the practice of the pharmaceutical industry following the application of the methods to efficacy studies. Project plan: To reach the proposed objectives, the FLUCOP project is composed of five focused interconnected work packages(WP). WP1:Standardization of HAI and VN assays. Objective: HAI and VN assays are commonly used to quantify influenza specific antibodies but they show to be highly variable between laboratories. Moreover different protocols are in use in different laboratories, which may contribute to the variability of the assays. This WP aims to improve the standardization and harmonization of these assays and also preparation and qualification of critical reagents. Methodology: Adult and paediatric pre and post influenza vaccination serum samples will be available to consortium partners who are recognized as leading experts in serological analysis of influenza vaccine responses. A target protocol profile will be developed jointly and statistically powdered studies will be design to compare, screen and evaluate consensus protocols. Sera will be analyzed in iterative rounds of testing of the empirically selected consensus protocols and assay conditions. A final data driven consensus protocol(s) for each HAI and VN format will agreed upon, based on the results o

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores